Additionally, GSK2795039 was developed as a NOX2-selective inhibitor [136] and improves systolic function and reduces cardiac hypertrophy in mouse models of myocardial infarction [137] and doxorubicin-induced cardiomyopathy [138,139], suggesting inhibition of NOX2-generated superoxide production may be a promising therapeutic approach. Here, CYBB is linked to cardiac hypertrophy.